Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04924322 · ClinicalTrials.gov registry record · Phase 2
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
A Phase 2 study of Deep Venous Thrombosis, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 258
- Enrollment target
- 20
- Study locations
NCT04924322 is a Phase 2 study of Deep Venous Thrombosis that is actively recruiting participants, run by Yale University. The registered enrollment target is 258 participants, below the 438-participant average among 9 other Deep Venous Thrombosis trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04924322, a Phase 2 study of Deep Venous Thrombosis, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 258 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.
Conditions Studied
Interventions
- DRUG Enoxaparin
Study Locations (20)
New York
- Hassenfeld Children's Hospital - New York
- New York Presbyterian Hospital - New York
- Golisano Children's Hospital - Rochester
- Maria Fareri Children's Hospital - Valhalla
Florida
- University of Florida -UF Health - Gainesville
- Johns Hopkins All Children's - St. Petersburg
Ohio
- UH Rainbow Babies & Children's Hospital - Cleveland
- Nationwide Children's Hospital - Columbus
Pennsylvania
- Penn State Hershey Children's Hospital - Hershey
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Dell Children's Medical Canter - Austin
- UTSW Medical Center; Children's Medical Center of Dallas - Dallas
Alabama
- Children's of Alabama - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04924322
The ClinicalTrials.gov registry entry for NCT04924322 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 438-participant average among 9 other Deep Venous Thrombosis trials with a reported enrollment target (41% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Deep Venous Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Enoxaparin is the first listed.
NCT04924322 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT04924322 about?
NCT04924322 is a clinical study titled "Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies". The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.
What is the current status of trial NCT04924322?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 258 participants. The study started on 2022-05-11. Estimated completion is 2026-07-31.
What conditions does trial NCT04924322 study?
This clinical trial studies the following conditions: Deep Venous Thrombosis.
What interventions are being tested in trial NCT04924322?
The interventions under investigation include: Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT04924322?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04924322 being conducted?
This trial has 20 study locations across Alabama, Arkansas, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Deep Venous Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
COMPLETED · Phase 2
-
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
RECRUITING · NA
-
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
RECRUITING · NA
-
FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease
ACTIVE NOT RECRUITING
-
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
ACTIVE NOT RECRUITING · Phase 3
-
The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.